Podcasts about mabs

Please visit answersincme.com/CKC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evolving role of OX40/OX40L-targeted monoclonal antibodies (mAbs) for the treatment of moderate to severe atopic dermatitis.Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting OX40/OX40L in the treatment of moderate to severe atopic dermatitis (AD); Review the clinical profiles of OX40/OX40L-targeted monoclonal antibodies in treating moderate to severe AD; and Outline clinical considerations for the future integration of OX40/OX40L-targeted mAbs into treatment plans for moderate to severe AD.

Ursula Collins from MABS chats to JP about a money management and avoiding fraud event Hosted on Acast. See acast.com/privacy for more information.

FDA's plan to move away from animal toxicity testing could expedite INDs and cut costs for biopharma companies, while helping the U.S. maintain its position as a clinical research hub. On the latest BioCentury This Week podcast, BioCentury's editors discuss the agency's new three-year road map to reduce animal safety studies for mAbs. The editors then discuss the deepening morale crisis at FDA after HHS Secretary Robert F. Kennedy Jr. accused the agency of corruption, encouraged staff to report supervisors over approval decisions they oppose, and endorsed conspiracy theories about the “deep state.” They assess the impact of whipsawing tariff policies and turmoil at FDA on biotech indexes — and why the sky isn't falling just yet for biotech's specialist investors. The editors also highlight recent stories on base editors' efficiency boom and how exosomes are finding new life. This episode of BioCentury This Week podcast was sponsored by RemeGen.View full story: https://www.biocentury.com/article/65562200:01 - Sponsor Message: RemeGen Co.02:38 - Replacing Animal Models09:40 - RFK Jr. & FDA19:36 - NIH30:02 - BioPharma Market Pulse33:23 - Innovation HighlightsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Send us a textSeason 2, Episode 36Its a chance for the boy's to get together again today and have a chat.Although Martin gave us an update on his Cancer this week we delve into his current treatment "Immunotherapy" and its possible side effects.Immunotherapy uses our immune system to fight cancer. It works by helping the immune system recognise and attack cancer cells.You might have immunotherapy on its own or with other cancer treatments. Immunotherapy is a standard treatment for some types of cancer. And it is in clinical trials  for other types of cancer.There are different types of immunotherapy. We have information about the following types of immunotherapies:monoclonal antibodies (mAbs)checkpoint inhibitorsvaccinescytokinesCAR T-cell therapySome types of immunotherapies are also called targeted treatments or biological therapies. The boy's also talk about the touchy subject of Piles (Hemorrhoids) rhyming cockney slang "Farmer Giles" Piles, discussing diagnosis, causes and treatments.Hemorrhoids (HEM-uh-roids), also called piles, are swollen veins in the anus and lower rectum. Hemorrhoids are similar to varicose veins. Hemorrhoids can develop inside the rectum, called internal hemorrhoids. They also can develop under the skin around the anus, called external hemorrhoidsThere is also a chance for Martins Joke of the weekAnd don't forget if you live in the UK don't forget to put your clocks forward on Saturday night.#HeartTransplant#EbsteinsAnomaly#RareCondition#HealthJourney#LifeChangingDiagnosis#MentalHealth#Vulnerability#SelfCompassion#PostTraumaticGrowth#MedicalMiracle#BBCSports#Inspiration#Cardiology#Surgery#Podcast#Healthcare#HeartHealth#MedicalBreakthrough#EmotionalJourney#SupportSystem#HealthcareHeroes#PatientStories#CardiologyCare#MedicalJourney#LifeLessons#MentalWellness#HealthAwareness#InspirationalTalk#LivingWithIllness#RareDiseaseAwareness#SharingIsCaring#MedicalSupport#BBCReporter#HeartDisease#PodcastInterview#HealthTalk#Empowerment#Wellbeing#HealthPodcast#DNACheck out our new website at www.whostomanddick.comCheck out our website at www.whostomanddick.com

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-triage-and-imaging-in-the-emergency-setting-for-patients-prescribed-anti-a-mabs/30022/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-evolving-approaches-to-mitigate-aria-risk-in-patients-prescribed-anti-a-mabs/27044/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-when-is-a-headache-concerning-in-patients-prescribed-anti-a-mabs/27040/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

Host: James R. Bateman, MD, MPH Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM Guest: Jerome A. Barakos, MD Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

Host: James R. Bateman, MD, MPH Guest: Charles P. Vega, MD Guest: B. Joy Snider, MD, PhD Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

Host: James R. Bateman, MD, MPH Guest: B. Joy Snider, MD, PhD Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

Jana geht einer Frage aus der Alpin-Fortbildung des IhF nach: Macht Schweinefleisch Rheuma? Gibts da Evidenz? Der Epidemiologe der Herzen, Hannes B. aus M., hat für uns die Leitlinie zu Vitamin D der endokrine society gelesen und Ilja spekuliert über den neuen heißen Scheiß in Sachen Antikoagulation, streift Tirzepatid und aktualisiert noch mal den Stand der Dinge zu Vorhofflimmer-Screening.

CME credits: 0.50 Valid until: 23-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/time-out-a-case-based-deep-dive-into-the-challenges-of-aria-management/26588/ Amyloid-related imaging abnormalities (ARIA) can represent a significant clinical challenge in the acute management of some patients with Alzheimer's disease receiving anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs). "Time Out: A Case-Based Deep Dive into the Challenges of ARIA Management" is an educational program designed to enhance clinicians' practical skills through the examination of complex, real-world case scenarios. This interactive program equips all members of the multidisciplinary care team with effective strategies for acute ARIA management, fostering confidence in handling intricate emergency situations. Join our expert panel to deepen your expertise and contribute meaningfully to patient care in the evolving landscape of ARIA.=

Host: James R. Bateman, MD, MPH Guest: Jerome A. Barakos, MD Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM Guest: B. Joy Snider, MD, PhD Amyloid-related imaging abnormalities (ARIA) can represent a significant clinical challenge in the acute management of some patients with Alzheimer's disease receiving anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs). "Time Out: A Case-Based Deep Dive into the Challenges of ARIA Management" is an educational program designed to enhance clinicians' practical skills through the examination of complex, real-world case scenarios. This interactive program equips all members of the multidisciplinary care team with effective strategies for acute ARIA management, fostering confidence in handling intricate emergency situations. Join our expert panel to deepen your expertise and contribute meaningfully to patient care in the evolving landscape of ARIA.

CME credits: 0.50 Valid until: 19-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/an-overview-of-aria-a-multidisciplinary-crash-course-for-baseline-clinical-needs/26587/ Amyloid-related imaging abnormalities (ARIA) can pose a significant challenge in the management of Alzheimer's disease, necessitating a collaborative, interdisciplinary approach. "The ARIA Toolkit: An Interdisciplinary Curriculum" is a comprehensive program designed to equip healthcare professionals with in-depth knowledge and practical skills for effective ARIA management. Featuring the latest advances in anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs), this educational format aims to prepare participants for real-world scenarios. Join our panel of expert faculty in this essential session to enhance team-based strategies and optimize patient outcomes.=

Host: James R. Bateman, MD, MPH Guest: Jerome A. Barakos, MD Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM Guest: B. Joy Snider, MD, PhD Guest: Charles P. Vega, MD Amyloid-related imaging abnormalities (ARIA) can pose a significant challenge in the management of Alzheimer's disease, necessitating a collaborative, interdisciplinary approach. "The ARIA Toolkit: An Interdisciplinary Curriculum" is a comprehensive program designed to equip healthcare professionals with in-depth knowledge and practical skills for effective ARIA management. Featuring the latest advances in anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs), this educational format aims to prepare participants for real-world scenarios. Join our panel of expert faculty in this essential session to enhance team-based strategies and optimize patient outcomes.

BUFFALO, NY - December 11, 2024 – A #news feature on the #research paper “Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition” by Rackear et al. was #published in Oncotarget's Volume 15 on November 22, 2024, titled “Advancements in cell-penetrating monoclonal antibody treatment." This new publication by Sai Pallavi Pradeep and Raman Bahal from the Department of Pharmaceutical Sciences at the University of Connecticut highlights significant advancements in monoclonal antibody (mAb) therapies. The focus is on the 3E10 antibody, originally derived from autoimmune mouse studies in systemic lupus erythematosus. Unlike traditional mAbs, which struggle to reach intracellular targets, this cell-penetrating antibody targets cancer cells by addressing a major limitation of current therapies. By targeting RAD51, a key intracellular protein involved in DNA repair, the 3E10 antibody shows great promise for cancer treatment, particularly in cancers with defective DNA repair pathways. mAbs have already changed the landscape of cancer therapy, offering treatments that are more targeted and have fewer side effects compared to chemotherapy. However, current therapies are limited since mAbs only target proteins on the surface of cancer cells. This research pushes the boundaries by demonstrating how 3E10 antibodies can penetrate cells and access their internal molecules. This unique capability expands the potential of mAb therapies and targeted cancer treatments. Different humanized versions of the 3E10 antibody were created and carefully tested. Some versions were particularly effective at blocking RAD51, while others showed promise for carrying other therapeutic molecules like genetic material into the cancer cells. This flexibility means that 3E10 could be used to treat different cancer types and deliver various therapeutic molecules directly into tumor cells. This progress offers exciting new possibilities for treating cancer tumors that are resistant to conventional therapies. In conclusion, the 3E10 antibody's dual function—targeting DNA repair pathways and delivering therapeutic molecules—positions it as a transformative tool in cancer research and targeted cancer treatments. DOI - https://doi.org/10.18632/oncotarget.28674 Correspondence to - Raman Bahal - raman.bahal@uconn.edu Video short - https://www.youtube.com/watch?v=3uMdPvThFHA Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28674 Subscribe for free publication alerts from Oncotarget: https://www.oncotarget.com/subscribe/ Keywords - cancer, monoclonal anti-bodies, cell penetration, nucleic acid delivery, 3E10 About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

A substantial part of the biopharma ecosystem involves deals between biotechs and academics, with smaller companies accessing assets to add to their pipelines and technologies to help solve problems. On the latest BioCentury This Week podcast, BioCentury's editors discuss the interplay of biotech and academia, including how deals between the groups often come outside the hubs of Boston and the Bay Area and what types of indications and technologies are common focus points. They also discuss new data in Alzheimer's for Leqembi from Eisai and Biogen that provide insight into how to get the most out of anti-amyloid mAbs for the disease, and what's next for James Wilson now that the gene therapy pioneer is moving on from the University of Pennsylvania.View full story: https://www.biocentury.com/article/65317400:00 - Intro04:25 - Biotech-Academia Deals12:04 - Leqembi's Latest Data19:20 - What's Next for James Wilson

In his weekly clinical update, Dr, Daniel Griffin reviews President Biden's case of COVID, reviews recent statistics on SARS-CoV-2 infection, discusses post-acute sequelae after infection during pregnancy, the use of nirmatrelvir-ritonavir for post-exposure prophylaxis, where to find Pemgarda, effectiveness of combined nirmatrelvir-ritonavir-molnupiravir treatment, effectiveness of Ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19, effectiveness of combined nirmatrelvir-ritonavir-molnupiravir treatment in patients hospitalized with COVID-19, CDC update of Long COVID Basics page, postacute sequelae of SARS-CoV-2 infection in the pre-delta, delta, and omicron eras, Long COVID risk has dropped over time but remains substantial, efficacy of antivirals, corticosteroids, and mAbs as acute COVID treatments in reducing the incidence of long COVID, and the interplay between diet and the gut microbiome: implications for health and disease. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode President Biden has COVID (CNN, USA Today) COVID-19 national trend (CDC) COVID-19 deaths (CDC) Post–acute sequelae of COVID after infection during pregnancy (OB & Gyn) Oral nirmatrelvir–ritonavir as postexposure prophylaxis for Covid-19 (NEJM) Pemgarda infusion center locator (Pemgarda) Unable to access pemgarda, gotta call Daniel (microbeTV) CDC Quarantine guidelines (CDC) Early phase of SARs-CoV-2 infection (COVID.gov) NIH COVID-19 treatment guidelines (NIH) Infectious Disease Society guidelines for treatment and management (ID Society) Drug interaction checker (University of Liverpool) Combined treatment of COVID reduces molnupiravir-induced mutagenicity (J Inf Dis) Effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19 (Inf Dis Therapy) Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy (Lancet) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) Isolation guidance (CDC) Managing healthcare staffing shortages (CDC) Steroids, dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Long COVID is defined (National Academies) Long COVID: the ANSWERS! (longcovidtheanswers.com) The FACTS: post COVID-19=long COVID? (WHO) The BASICS of long COVID-19 (CDC) Postacute sequelae of SARS-CoV-2 infection in the pre-delta, delta, and omicron eras (NEJM) Long Covid risk has dropped over time but remains substantial (CNN) Efficacy of antivirals, corticosteroids, and mAbs as acute COVID treatments in reducing the incidence of long COVID (Clin Micro Inf) Diet and the gut microbiome: implications for health and disease (Nat Rev Micro) Contribute to our Floating Doctors fundraiser Letters read on TWiV 1132 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Kristin is joined by Professor Sanjay Swaminathan to talk all things MABs or monoclonal antibodies. Dr Sanjay Swaminathan is a Clinical Immunologist and Allergist, he is a Senior Staff Specialist and Head of the Department of Immunology and Allergy at Westmead and Blacktown Hospitals.

Featuring articles on treatments for eosinophilic esophagitis, reteplase versus alteplase for acute ischemic stroke, dupilumab for COPD with type 2 inflammation, and brigatinib in NF2-related schwannomatosis; a review article on amyloidosis; a case report of a man with recurrent fever and liver lesions; and Perspectives on Alzheimer's disease, biomarkers, and mAbs; on climate litigation for protecting public health; on carbon-footprint analyses in RCTs; and on the phantom of the organ.

TNF-α Inhibitors and Monoclonal Antibodies mABs (WBH with Dr. Saleeby Ep. 17) Learn more about Whole Body Health: https://covid19criticalcare.com/courses/whole-body-health-with-dr-saleeby/ In this episode of Whole Body Health, Dr. JP Saleeby discusses TNF-α inhibitors and monoclonal antibodies (mABs) as treatments for autoimmune diseases like Crohn's disease and Rheumatoid Arthritis. Learn what TNF-α blockers are, their uses, and alternatives available. Dr. Saleeby shares concerns about the newness of some mABs, the lack of extensive safety data, and potential side effects. We'll also learn about the risks associated with anti-TNF therapy, including reduced immunity leading to infections such as tuberculosis and histoplasmosis, and the possibility of developing certain cancers and autoimmune conditions. Dr. Saleeby emphasizes the importance of being informed about these treatments, their adverse side effects, and why careful consideration is needed before starting therapy with TNF-α inhibitors and monoclonal antibodies Dr. JP Saleeby | Carolina Holistic Medicine
 https://carolinaholisticmedicine.com/ Dr. JP Saleeby's Substack | Yusuf's Substack
 https://jpsaleebymd.substack.com/ The FLCCC Alliance is a healthcare nonprofit on a mission to restore trust, integrity, and the doctor-patient relationship. Get involved by clicking below: • Donate: https://geni.us/Donate-Today 
 • Follow: https://geni.us/Follow-FLCCC 
 • Protocols: https://geni.us/Treatment 
 • Webinar: https://geni.us/FLCCC-Webinar 
 • Shop: https://geni.us/Shop-FLCCC Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only. Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

Dr Nancy Klimas, Director of the Institute for Neuro-Immune Medicine, Nova Southeastern University, is an immunologist internationally renowned for her work in multi-symptom illnesses.  In this week's episode she explains her work, from HIV through ME/CFS and Gulf War Syndrome, that has led to her having insight and an amazing team to channel efforts into Long Covid research and treatment.  In an insightful overview she describes her work in understanding the mechanisms (viral persistence, viral reactivation), impacts of (MCAS, cell dysfunction, T-cell dysregulation) and potential alleviation of the disease.  She has been involved in studies looking at clinical therapeutics such as LDN and has seen remarkable results with the use of MABs which she is hoping to replicate in a larger clinical trial in the coming weeks.Living with Long Covid? How was your week?Website - https://www.tlcsessions.net/Twitter - @SessionsTlc https://twitter.com/sessionstlcInsta - @tlcsessions https://www.instagram.com/tlcsessions

If you have trouble making your money stretch to the next payday or coping with an unexpected expense then Michelle O'Hara, National Spokesperson of MABS, has advice on how setting a household budget can help

MABS is the Irish money advice service. We have been supporting people with money advice, budgeting, and problem debt for 30 years. Our service is free of charge. We're here for you if you're struggling with debt and need help. You can get impartial advice from MABS to help you manage your money and take control of debt. We offer support online, over the phone and face to face.

We sit down with health care executive Eugene Chan to explore the rising rates of liver cancer worldwide and the potential game-changer in its treatment: monoclonal antibodies. Join us as we delve into the factors contributing to liver cancer's prevalence, the impact of vaccination, and the promising future of mAbs as a more precise and effective treatment approach. Discover the latest research on bi-specific antibodies and the ongoing efforts to improve outcomes for patients battling hepatocellular carcinoma (HCC). Eugene Chan is a health care executive. He discusses the KevinMD article, "Diversified treatments are needed to fight the increasing threat of liver cancer." Our presenting sponsor is Nuance, a Microsoft company. Together, Microsoft and Nuance are leveraging their rich digital technology and advanced AI capabilities to tackle some of health care's biggest challenges. AI-driven technology promises to revolutionize patient and provider experiences with clinical documentation that writes itself. The Nuance Dragon Ambient eXperience, or DAX for short, is a voice-enabled solution that automatically captures patient encounters securely and accurately at the point of care. DAX Copilot combines proven conversational and ambient AI with the most advanced generative AI in a mobile application that integrates directly with your existing workflows. Physicians who use DAX have reported a 50 percent decrease in documentation time and a 70 percent reduction in feelings of burnout, and 85 percent of patients say their physician is more personable and conversational. Discover AI-powered clinical documentation that writes itself. Visit https://nuance.com/daxinaction to see a 12-minute DAX Copilot demo. VISIT SPONSOR → https://nuance.com/daxinaction SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://earnc.me/FT8GkE Powered by CMEfy. 

What strategies can reduce development time and accelerate access to next-generation monoclonal antibodies (mAbs) in the evolving SARS-CoV-2 variant landscape? Credit available for this activity expires: 1/26/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/999900?ecd=bdc_podcast_libsyn_mscpedu

Over the last month listeners to Radio Kerry were invited to nominate the individuals or groups they considered made them proudest to be from Kerry over the last year. The awards are sponsored by Fexco and the 8 recipients received a specially commissioned piece by Louis Mulcahy. Ryan Griffin from Waterville was nominated by listeners for his silver medal win at the Special Olympics, and he was joined by Crotta hurlers for bringing a 55 year wait to an end and winning the County Hurling Final. Participants and host farmers in the Kerry Social Farming project were also recognised for the difference they make in our community. Lynne Fenton, Liz Fenton and Deirdre O Callaghan were nominated for the support they showed the Fenton Toms family after a devastating house fire. There was also a Local Hero award for Paddy Kevane for the work he does with St Vincent de Paul, Meals on Wheels and MABS. Deirdre Fitzgerald and the staff at the O Connell Adult Centre in Caherciveen were recognised for the support they give to those returning to education. Listeners nominated Louise Quill for her work with the Tir na n Og orphanage in Tanzania, and Billy Browne from Killorglin for the exceptional care he showed to his late son Conor which facilitated him to be cared for at home. This award also recognised the exceptional work down by family carers throughout the county. Radio Kerry General Manager, Fiona Stack said that the nominations showed how lucky we are to live in a community where so many groups and individuals step forward to help others. She congratulated the winners and the multiple other nominees, and thanked listeners for bringing their stories forward for recognition and allowing us end the year celebrating those that make us proud to be from Kerry.

Today, we're pleased to share with you an audio essay written and read by Matthew Martens, entitled, "3 Things That Must Change about the American Justice System". Matthew T. Martens (JD, University of North Carolina School of Law; MABS, Dallas Theological Seminary) is a trial lawyer and partner at an international law firm in Washington, DC. He has spent the bulk of his more than twenty-five-year legal career practicing criminal law both as a federal prosecutor and as a defense attorney. He served as a law clerk to Chief Justice William Rehnquist at the US Supreme Court and also as a political appointee in the criminal division of the US Justice Department under Attorney General Ashcroft. His new book with Crossway is called 'Reforming Criminal Justice: A Christian Proposal'. Read the essay here. If you enjoyed this episode be sure to leave us a review, which helps us spread the word about the show!

In this podcast Dr Anna Volkmer, convenes a panel of world-renowned experts from University College London. They discuss the discovery of amyloid and its role in Alzheimer's Disease and take an in-depth look into the latest developments surrounding Lecanemab and Donanemab, monoclonal antibodies (mAbs) as a treatment and Gene Silencing. This week's guests are Professor Sir John Hardy, Geneticist and trailblazer in neurodegenerative disease research, Professor Nick Fox, Neurologist, and eminent figure in the fields of neuroimaging and clinical neuroscience, and Dr Cath Mummery, Neurologist and leading light in cognitive disorders and clinical trials. -- Listeners can expect: 1.

In this episode, trial lawyer Matt Martens explains how our American criminal justice system is broken and that in order for us to love all of our neighbors well, reforms need to be made. Matt Martens (JD, University of North Carolina School of Law; MABS, Dallas Theological Seminary) is a trial lawyer and partner at an international law firm in Washington, DC. He has spent the bulk of his more than twenty-five-year legal career practicing criminal law both as a federal prosecutor and as a defense attorney. He is also the author of 'Reforming Criminal Justice: A Christian Proposal' from Crossway. Read the full transcript of this episode. If you enjoyed this episode be sure to leave us a review, which helps us spread the word about the show! Complete this survey for a free audiobook by Kevin DeYoung!

Michelle O'Hara National Spokesperson for MABS shares how you make some savings this Christmas.

Victoria har stökat i trädgården, gjort plats för vinterförvaring i garaget och burit tunga krukor. Något som lett till en lite kylig stämning mellan henne och poolsvetsarn. Jenny har också varit ute i den friska höstluften och pillat, köpt lite för dyra kuddfodral och lagat lammlägg. I veckans avsnitt får Victoria prata till punkt beträffande pioner och fördjupar sig i cyklamen, denna ofta bortglömda lilla krukväxt som piggar upp i fönsterblecket. Vilka sorter finns? Hur ska man tänka kring matchning? Och hur får man de att vara fina så länge som möjligt?Dessutom blir det TikTok-algoritmer, kommande samboskap och Halloweenskepsis Mejla till oss: rodavitarosenpodden@gmail.com Länk till MABS kompressionsstrumpor: https://www.apotea.se/mabs?utm_source=Podd&utm_medium=partnership&utm_campaign=kp_se_mabs_podd Hosted on Acast. See acast.com/privacy for more information.

Em 1987, quatro pessoas desapareceram em Reno nos Estados Unidos sem deixar rastros. Era para ser mais um dia normal de trabalho, mas quando o pai de uma delas percebeu a demora da filha para voltar para casa ele se apavorou. Aquilo nao era comum. Sua filha era jovem, estava acompanhada e já deveria estar em casa. Como duas das desaparecidas eram menores de idade, o FBI logo se envolveu e começou uma busca que se revelou surpreendente mas mais ainda, grotesca com enormes mentiras.  Ouça agora a história de Mabs, Dottie, Monica e Alecia. --- Send in a voice message: https://podcasters.spotify.com/pod/show/guria-studios/message

Join us as we review recent articles and news featured in The DIGEST #43 and #44, including bempedoic acid to lower cardiovascular risk, Alpha-Gal Syndrome, tick bites and meat allergy, orforglipron an oral GLP1 agonist for weight loss, zuranolone for postpartum depression, DOACs for VTE of malignancy, monoclonal antibodies (mAbs) for Dementia, cytisinicline for smoking cessation, and two kiwis a day for constipation. Fill your brain hole with a delicious stack of hotcakes! Featuring Drs. Paul Williams (@PaulNWilliamz), Nora Taranto (@norataranto), and Matt Watto (@doctorwatto). Claim free CME for this episode at curbsiders.vcuhealth.org! Episodes | Subscribe | Spotify | Swag! |Mailing List | Contact | Free CME! Credits Written and Hosted by: Nora Taranto MD; Paul Williams, MD, FACP, Matthew Watto MD, FACP Cover Art: Matthew Watto MD, FACP Reviewers: Nora Taranto MD; Paul Williams, MD, FACP, Matthew Watto MD, FACP Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Sponsor: Netsuite Download NetSuite's popular KPI Checklist, designed to give you consistently excellent performance for free, at NetSuite.com/CURBSIDERS Sponsor: Locumstory  Get a comprehensive view of locums and decide if it's right for you at locumstory.com. Sponsor: Grammarly  Go to grammarly.com/GO to download for FREE today. Sponsor: Pathway Download the Pathway app today by visiting pathway.md Show Segments Intro, disclaimer Bempedoic Acid for CV risk reduction DOACs to prevent recurrent VTE of malignancy Cytisinicline for smoking cessation Alpha-Gal Syndrome, tick bites, and meat allergy Zuranolone for postpartum depression Orforglipron, an oral GLP1 agonist, for weight management mAbs for Alzheimer's dementia Kiwis to prevent constipation Outro

Biotherapies are big news in veterinary medicine. They include monoclonal antibodies — or mAbs…

Biotherapies are big news in veterinary medicine. They include monoclonal antibodies — or mAbs [pronounced as a word, not letters: măbs] — and agents that boost the immune system. mAbs...

Ted Shimer has mentored men since 1991 with the collegiate ministry Student Mobilization. He received his MABS from Dallas Seminary and has been trained as a Pastoral Sex Addiction Professional-Supervisor. Ted has helped people overcome the bondage of pornography in the context of making disciples throughout his 30 plus year ministry. He is the Founder of The Freedom Fight, an online porn addiction recovery program. He is also the author of the book, The Freedom Fight, The New Drug and the Truths that Set Us Free. Ted and his wife Amber have four adult children and live in Fayetteville, Arkansas. Visit their website at thefreedomfight.org --- Support this podcast: https://podcasters.spotify.com/pod/show/moral-revolution/support

Wendy Wilson, mission advisor for the Development of Women for Missio Nexus, is convinced that women and men are designed for full and equal partnership in ministry, and it shows! In this episode, Wendy challenges the church to awaken to that vision, and she provides one way to get there: safe, experiential spaces to talk about the theology and practice of mixed-gender ministry partnership. Listen and be inspired—as Wendy notes, change is happening!    Guest Bio:  Having served in various capacities in leadership training ministry since 1984, Wendy's great joy is envisioning and equipping women to participate fully in living out their design in the Image of God and in the grand calling of the Great Commission. With a BBA from Texas A&M University and an MABS from Dallas Theological Seminary, Wendy has led inter-mission and inter-confessional mentoring and equipping efforts for 30+ years, having lived and traveled abroad for many of those years. After serving for twenty-eight years with a pastoral training mission, with a focus on engaging women with shepherding gifts, she has served since 2012 as the mission advisor for Development of Women to the Missio Nexus network of mission agencies, and as the founder and executive director of the collaborative Women's Development Track.    More info on Missio Nexus and Wendy's ministry:    Missio Nexus  Women's Development Track    Other Resources:    CBE eLearning Course: Beyond Bias: Aligning towards God's Vision for Women and Men in Bible Translation    The Ministry of Women in the New Testament: Reclaiming the Biblical Vision for Church Leadership    How to Teach Mutuality to the Next Generation    Disclaimer:  The opinions expressed in CBE's Mutuality Matters' podcast are those of its hosts or guests and do not purport to reflect the opinions or views of CBE International or its members or chapters worldwide. The designations employed in this podcast and the presentation of content therein do not imply the expression of any opinion whatsoever on the part of CBE concerning the legal status of any country, area or territory or of its authorities, or concerning the delimitation of its frontiers. 

Gwen Harris the regional manager of MABS The Money Advice and Budgeting Service sits down and talks financial wellbeing with James and Timmy.Gwen has over 25 years of experience in client and community advocacy and education roles and is the perfect person to discuss the importance of financial wellbeing.More information on MABS - https://mabs.ie/ Help us help others by joining our Patreon...Why not become a Patron of the Two Norries to help us help you and others? We're always happy to receive donations which all go towards bills, production costs, maintenance and everything else it takes to keep the podcast alive.Donations can be as little as €1 or as much as you can afford. To sign up simply CLICK HERE, thank you Two Norries Podcast Hosted on Acast. See acast.com/privacy for more information.

A new research perspective was published in Oncotarget's Volume 14 on June 19, 2023, entitled, “Targeting GITR in cancer immunotherapy – there is no perfect knowledge.” In this new perspective, researchers Diwakar Davar and Roberta Zappasodi from the University of Pittsburgh Medical Center (UPMC), University of Pittsburgh, Weill Cornell Medical College, and Weill Cornell Graduate School of Medical Sciences discuss the glucocorticoid-induced TNFR-related protein (GITR), belonging to the TNFR superfamily (TNFRSF) and stimulating both the acquired and innate immunity. GITR is broadly expressed on immune cells, particularly regulatory T cells (Tregs) and natural killer (NK) cells. “Given its potential to promote T effector function and impede Treg immune suppression, GITR is an attractive target for cancer immunotherapy.” Preclinically, GITR agonists have demonstrated potent anti-tumor efficacy singly and in combination with a variety of agents, including PD-1 blockade. Multiple GITR agonists have been advanced into the clinic, although the experience with these agents has been disappointing. Recent mechanistic insights into the roles of antibody structure, valency, and Fc functionality in mediating anti-tumor efficacy may explain some of the apparent inconsistency or discordance between preclinical data and observed clinical efficacy. Overall, the clinical results obtained so far with GITR agonist agents have demonstrated specific immune effects in the expected immune cell populations based on preclinical studies. However, these effects have not produced substantial therapeutic activity in human cancer patients. A maturing understanding of the immune responses to GITR agonism in human cancer has clarified novel issues specific to drug development in this space including Ab structure (monospecific and bispecific mAbs and co-stimulatory GITR ligands), Ab valency, and Fc functionality. “This improved understanding of the immune responses to GITR agonism in patients should be kept in consideration for the design of novel rational combinations or treatment regimens in earlier disease settings where immunotherapy is gradually becoming the treatment of choice.” DOI - https://doi.org/10.18632/oncotarget.28461 Correspondence to - Diwakar Davar - davard@upmc.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28461 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, immunotherapy, programmed death-1 (PD-1), cytotoxic T-lymphocyte Antigen-4 (CTLA-4), glucocorticoid-induced TNFR-related protein (GITR) About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Michelle O'Hara, national spokesperson for MABS on today's launch of the Banking Payments Federation and MABS campaign targeted at those concerned about mortgage payments.

Many are talking about multi-armed bandits (MAB) killing CRO - is there truth to that? The answer: it depends! In this episode, Tracy and Shiva discuss: 00:00 Intro 03:04 What are MABs? 04:45 Are MABs “real” tests? 06:23 Why do people find MABs so sexy? 09:15 When you should (and shouldn't) run a MAB 13:58 How to validate your MAB results 16:41 LinkedIn post of the week The LinkedIn post of the week is from Ryan Lucht: https://tinyurl.com/FromAtoBRyan Like what you hear? Subscribe. All the cool kids are doing it.

They've got an AgriVision because they AgriCare. As Todd talks with Scott Mabs of Homegrown Organic Farms, you will discover that they plan for future success by providing services to protect and enhance small to mid-size family farms. Who are these folks? They are growers and marketers of certified organic produce who take their pledge of stewardship of the soil, people, and the planet seriously. Lots to unpack. Everything from the meaning of organic to regenerative cross-overs. This talk is worth a listen.

In this series we're going to meet and chat to state agencies, experts and specialists to explain what your rights are, what services and entitlements exists and where you can go for help. Today I am meeting with Gwen Harris, who is North Dublin Regional Manager for MABS, the Money Advice & Budgeting Service. I thought I knew a little bit about it but there is a lot more. MABS provides clear advice and guidance for people who have hit financial difficulties or problems with debt. It is non-judgemental, practical and according to the many people who have used the service it is invaluable. The Abhaile service is specifically to help when people have mortgage arrears. Gwen will talk me through the detail of that one in a separate podcast because there is a lot in it. For today, she explains how the general MABS service works and why so many people find it so helpful.

Today I am meeting with Gwen Harris, who is North Dublin Regional Manager for MABS, the Money Advice & Budgeting Service. I thought I knew a little bit about it but there is a lot more. MABS provides clear advice and guidance for people who have hit financial difficulties or problems with debt. It is non-judgmental, practical and according to the many people who have used the service it is invaluable.

TWiV to explains a study on presence of COVID-19 vaccine mRNA in the blood, and the isolation of cross-protective monoclonal antibodies against common endemic respiratory viruses. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode •Register for ASV 2023 •MicrobeTV Discord Server •Paul Berg obituary •Spike mRNA in blood (J Path Micro Imm) •Spike mRNA in blood (Biomedicine) •Cross-protective mAbs against respiratory viruses (Nat Comm) •RSV prefusion F protein vaccine in older adults (NEJM) •Ad26.RSV.preF–RSV preF protein vaccine (NEJM) •Letters read on TWiV 989 •Timestamps by Jolene. Thanks! Weekly Picks Dickson – Jazz Project: Drums: Sunny Payne (Count Basie Orchestra); Buddy Rich (Count Basie Orchestra); Rufus Jones (Maynard Ferguson Orchestra); Joe Morello (Dave Brubeck Quartet). Brianne – A Scientific Investigation of ‘The Last of Us' Fungal Pandemic Kathy – “That's What They Say” podcast about pronunciation of “primer.” Rich – Slow motion art:  1 and 2 Vincent – Grammarly Listener Pick Charles – Psychologist Daniel Levitin dissects Pink Floyd's ‘Dark Side of the Moon' Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

Fernando Carnavali, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss how new COVID-19 vaccines may affect risk stratification, including:Omicron-specific vaccineRole of vaccination in risk stratificationPresenters:Fernando Carnavali, MDAssociate Professor of MedicineDivision ChiefGeneral Internal MedicineDepartment of MedicineSite Director COVID Center of Excellence Satellite-AnsoniaMount Sinai Health SystemNew York, New YorkRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisJoseph Torrisi, PharmD, BCIDPClinical Pharmacy SpecialistInfectious DiseasesPharmacyGrady Health SystemAtlanta, GeorgiaLink to slides:https://bit.ly/3WDYeFKLink to full program: https://bit.ly/3WJdIbs

Neil talks to Minister for Foreign Affairs and Defence, Simon Coveney, following the death of an Irish soldier in the Lebanon last night. We hear from MABS and SVP as fuel poverty continues across the country, and comedian Mario Rosenstock accuses Neil of a heinous crime!Tune into the Neil Prendeville show weekdays from 9am on Cork's Red FM

This week on Pharm5: Tamiflu backorder ADHD medications & CVD risk Paxlovid dispensing guidance EUA pulled for last remaining COVID-19 monoclonal antibody ASHP Midyear Meeting Connect with us! Listen to our podcast: Pharm5 Follow us on Twitter: @LizHearnPharmD References: Current drug shortages. ASHP. https://bit.ly/3Fk0Keo. Accessed December 1, 2022. Center for Drug Evaluation and Research. Drug shortages. U.S. Food and Drug Administration. https://bit.ly/3B2DGhC. Accessed December 1, 2022. Weekly U.S. Influenza Surveillance Report. Centers for Disease Control and Prevention. https://bit.ly/3gQ77MW. Published November 28, 2022. Accessed December 1, 2022. Zhang L, Yao H, Li L, et al. Risk of cardiovascular diseases associated with medications used in attention-deficit/hyperactivity disorder. JAMA Network Open. 2022;5(11). doi:10.1001/jamanetworkopen.2022.43597 HQ APhA. APhA has created a pharmacist decision-making support tool for paxlovid. use it in your practices to help assess whether a prescription for Paxlovid is appropriate. Twitter. https://bit.ly/3H6F3Q7. Published November 30, 2022. Accessed December 1, 2022. FDA pulls U.S. authorization for Eli Lilly's Covid Drug Bebtelovimab. Reuters. https://bit.ly/3UiQyHa. Published November 30, 2022. Accessed December 1, 2022. Midyear clinical meeting 2022 - ASHP. MCM22. https://bit.ly/3B1dunI. Accessed December 1, 2022.

The International Nonproprietary Names (INN) unit from WHO decided to drop the -mab suffix from new drug names. Instead, -tug, -bart, -ment, and -mig will be used. We have some thoughts. INN Report: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122354/#